BioPharma Dive January 26, 2022
Jonathan Gardner

Dive Brief:

  • The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread elsewhere or grown too large to be surgically removed. The drug, called Kimmtrak, was developed by the U.K.-based biotech Immunocore.
  • The approval clears Kimmtrak as a treatment for uveal melanoma, a version of the aggressive skin cancer that appears in eye tissue. Less than 2,500 cases are diagnosed each year worldwide, with an estimated 400 eligible patients in the U.S.
  • Though immunotherapies from Merck & Co. and Bristol Myers Squibb are sometimes used to treat the disease, neither have won formal approvals to treat melanoma in eye tissue. Kimmtrak also outperformed Merck’s drug and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Brazil’s plan for low-cost CAR-Ts

Share This Article